Ponatinib use in two pediatric patients with relapsed Ph + ALL with ABL1 kinase domain mutations.
Stephanie E GrunerHadi SayeedLizmery Suarez-FergusonCintia PerezRayne RouceKevin E FisherRachel E RauPublished in: Pediatric hematology and oncology (2019)